Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer

Minamimoto, Ryogo; Loening, Andreas M.; Jamali, Mehran; Barkhodari, Amir; Mosci, Camila; Jackson, Tatianie; Obara, Piotr; Taviani, Valentina; Gambhir, Sanjiv S.; Vasanawala, Shreyas S.; Iagaru, Andrei

doi:10.2967/jnumed.115.162610

Cited by 97 publications

(43 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Minamimoto et al prospectively evaluated combined 18 F-NaF/ 18 F-FDG-PET/CT in comparison to wbMRI for the detection of osseous metastases in 15 patients with suspected or known metastatic prostate cancer. The group report 18 F-NaF/ 18 F-FDG-PET/CT superiority in the evaluation of skeletal disease, however suggest larger cohorts are required to confirm their preliminary findings (23). …”

Section: Discussionmentioning

confidence: 99%

Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy

et al. 2017

View full text Add to dashboard Cite

Purpose To report our initial experience using “whole body and dedicated prostate (WB+P)” MRI as a single exam for the assessment of local recurrence and metastatic disease in patients with suspected recurrent prostate cancer (PCa) after radical prostatectomy (RP). Materials and Methods IRB-approved retrospective single-center study. 76 consecutive patients with clinically suspected recurrent PCa following RP underwent combined WB+P-MRI in a single session (10/2014-01/2016). WB+P-MRI scans were evaluated for the detection of disease in the prostate bed, regional nodes and distant sites. Comparison was made to other imaging tests and prostate bed, node and bone biopsies, performed within 90-days. Results and Conclusions WB+P-MRI was completed successfully in all patients. Median PSA was 0.36 ng/ml (range:<0.05-56.12). WB+P-MRI identified suspected disease recurrence in 16/76 (21%) of patients (local recurrence in the RP bed in 6/76, nodal metastases in 3/76, osseous metastases in 4/76, and multifocal metastatic disease in 3/76). 43 patients had at least one standard staging scan in addition to WB+P-MRI, with concordance demonstrated between imaging modalities in 36/43(84%). All metastatic lesions detected on other imaging tests were detected on WB+P-MRI. In addition, WB+P-MRI detected osseous metastases in 4 patients with false-negative findings on other imaging tests (including 2 bone scans and 3 CT scans), and excluded osseous disease in 1 patient with a positive 18F-FDG-PET/CT, and subsequent negative bone biopsy. Whole body and pelvic (WB+P) MRI is feasible in a clinical practice setting, and can provide incremental information when compared to standard imaging in men with suspected PCa recurrence following RP.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…18F-NaF/FDG-PET/CT was found to be superior to whole body MRI and BS for evaluation skeletal disease in breast and prostate cancer, since it detects extra-skeletal disease which can significantly alter disease management. [8, 9]. …”

Section: 2 Diagnostic Approach To Bone Metastasesmentioning

confidence: 99%

Bone Pain and Muscle Weakness in Cancer Patients

Milgrom

Lad

Koniaris

et al. 2017

Curr Osteoporos Rep

View full text Add to dashboard Cite

Purpose of review In this article we will discuss the current understanding of bone pain and muscle weakness in cancer patients. We will describe the underlying physiology and mechanisms of cancer-induced bone pain (CIBP) and cancier-induced muscle wasting (CIMW), as well as current methods of diagnosis and treatment. We will discuss future therapies and research directions to help patients with these problems. Recent Findings There are several pharmacologic therapies that are currenly in pre-clinical and clinical testing that appear to be promising adjuncts to current CIBP and CIMW therapies. Such therapies include resiniferitoxin, which is a targeted inhibitor of nociptive nerve fibers, and selective androgen receptor modulators, which show promise in increasing lean mass. Summary CIBP and CIMW are a significant causes of morbidity in affected patients. Current management is mostly palliative; however, targeted therapies are poised to revolutionize how these problems are treated.

show abstract

“…Our results indicated the feasibility and utility of the combined administration of 18 F-NaF and 18 F-FDG in a single PET/CT examination for the detection of malignancy, including PC (17)(18)(19)(20).…”

Section: F-naf Pet/ct Vs 99m Tc-mdp Bone Scintigraphymentioning

confidence: 93%

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

et al. 2016

View full text Add to dashboard Cite

Although selective metabolic and receptor-based molecular agents will surely be included in the future of prostate cancer diagnosis and therapy, currently available inorganic compounds-such as 18 F-NaF for the diagnosis of bony disease and 223 RaCl 2 for the therapy of bone metastases-were recently shown to be superior to standard 99m Tcphosphonates for diagnosis and 153 Sm-ethylenediaminetetramethylene phosphonate or 89 SrCl 2 for therapy. The advantages of 18 F-NaF include improved lesion detection and, when used in combination with CT, improved diagnostic confidence and specificity. In addition to being the first approved α-emitter, 223 RaCl 2 is the first radiopharmaceutical to show an increase in overall survival, a decrease in skeletal events, palliation of bone pain, and a low profile of adverse reactions (which are mild and manageable). The management of metastatic bone disease with 223 RaCl 2 is uniquely satisfying, as patients can be monitored directly during their monthly treatment visits.

show abstract

Prospective Comparison of ^99mTc-MDP Scintigraphy, Combined ¹⁸F-NaF and ¹⁸F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer

Cited by 97 publications

References 26 publications

Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy

Combined Whole Body and Multiparametric Prostate Magnetic Resonance Imaging as a 1-Step Approach to the Simultaneous Assessment of Local Recurrence and Metastatic Disease after Radical Prostatectomy

Bone Pain and Muscle Weakness in Cancer Patients

Bone-Targeted Imaging and Radionuclide Therapy in Prostate Cancer

Contact Info

Product

Resources

About